Rankings
▼
Calendar
IMUX Q1 2021 Earnings — Immunic, Inc. Revenue & Financial Results | Market Cap Arena
IMUX
Immunic, Inc.
$138M
Q1 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$32M
Net Income
-$35M
EPS (Diluted)
$-1.63
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$13M
Free Cash Flow
-$13M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$155M
Total Liabilities
$17M
Stockholders' Equity
$137M
Cash & Equivalents
$115M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$32M
-$9M
-259.3%
Net Income
-$35M
-$8M
-306.9%
← FY 2021
All Quarters
Q2 2021 →